Natalie Compton

713 total citations
14 papers, 421 citations indexed

About

Natalie Compton is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, Natalie Compton has authored 14 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Reproductive Medicine. Recurrent topics in Natalie Compton's work include Ovarian cancer diagnosis and treatment (6 papers), PARP inhibition in cancer therapy (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Natalie Compton is often cited by papers focused on Ovarian cancer diagnosis and treatment (6 papers), PARP inhibition in cancer therapy (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Natalie Compton collaborates with scholars based in United Kingdom, United States and France. Natalie Compton's co-authors include Kevin J. Harrington, Nigel Biswas–Baldwin, Iman El‐Hariry, Hisham Mehanna, Philippe Legenne, Éva Remenár, Mike Lau, Jérôme Fayette, Fernando Hurtado de Mendoza and Martin Housset and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Natalie Compton

13 papers receiving 412 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Natalie Compton United Kingdom 9 255 164 139 126 62 14 421
Virag Dandekar United States 4 234 0.9× 151 0.9× 113 0.8× 109 0.9× 27 0.4× 6 527
J. Cheng United States 12 331 1.3× 148 0.9× 83 0.6× 150 1.2× 41 0.7× 27 504
O. Nascimben Italy 11 173 0.7× 60 0.4× 28 0.2× 118 0.9× 63 1.0× 21 352
Jst Sham Hong Kong 8 102 0.4× 110 0.7× 39 0.3× 109 0.9× 20 0.3× 19 394
A. Price United Kingdom 9 185 0.7× 191 1.2× 30 0.2× 252 2.0× 8 0.1× 14 509
Cyril Abdeddaim France 10 302 1.2× 92 0.6× 16 0.1× 77 0.6× 173 2.8× 30 519
Yasmine Baca United States 10 174 0.7× 83 0.5× 10 0.1× 94 0.7× 40 0.6× 56 292
A. Biete Spain 9 147 0.6× 119 0.7× 16 0.1× 112 0.9× 23 0.4× 25 425
Hammouda Boussen Tunisia 12 345 1.4× 167 1.0× 231 1.7× 187 1.5× 5 0.1× 57 708
Samuel Marcrom United States 12 221 0.9× 306 1.9× 41 0.3× 111 0.9× 7 0.1× 32 544

Countries citing papers authored by Natalie Compton

Since Specialization
Citations

This map shows the geographic impact of Natalie Compton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natalie Compton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natalie Compton more than expected).

Fields of papers citing papers by Natalie Compton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natalie Compton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natalie Compton. The network helps show where Natalie Compton may publish in the future.

Co-authorship network of co-authors of Natalie Compton

This figure shows the co-authorship network connecting the top 25 collaborators of Natalie Compton. A scholar is included among the top collaborators of Natalie Compton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natalie Compton. Natalie Compton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Liu, Joyce F., Stéphanie Gaillard, Andrea E. Wahner Hendrickson, et al.. (2024). Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. JCO Precision Oncology. 8(8). e2300693–e2300693. 6 indexed citations
3.
Pothuri, Bhavana, M.P. Barretina Ginesta, Whitney A. Spannuth Graybill, et al.. (2024). LBA29 Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012. Annals of Oncology. 35. S1222–S1223. 2 indexed citations
4.
5.
González-Martı́n, Antonio, Bhavana Pothuri, Ignace Vergote, et al.. (2023). Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. European Journal of Cancer. 189. 112908–112908. 55 indexed citations
6.
Martin, Andrew, Bhavana Pothuri, I. Vergote, et al.. (2022). 530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety. Annals of Oncology. 33. S789–S789. 16 indexed citations
7.
Mehanna, Hisham, Natalie Compton, Max Robinson, et al.. (2016). Geographic variation in human papillomavirus–related oropharyngeal cancer: Data from 4 multinational randomized trials. Head & Neck. 38(S1). E1863–9. 42 indexed citations
8.
Powles, Thomas, Sergio Bracarda, Chen Mei, et al.. (2015). Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients. European Journal of Cancer. 51(10). 1293–1302. 45 indexed citations
9.
Kendra, Kari, Ruth Plummer, Ravi Salgia, et al.. (2014). A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 14(2). 461–469. 28 indexed citations
10.
11.
12.
Campo, J.M. del, Ricardo Hitt, P. Sebastian, et al.. (2011). Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. British Journal of Cancer. 105(5). 618–627. 89 indexed citations
13.
Armsworth, Paul R., Natalie Compton, Ian D. Davies, et al.. (2010). The ecological research needs of business. Journal of Applied Ecology. 47(2). 235–243. 22 indexed citations
14.
Harrington, Kevin J., Max Robinson, Éva Remenár, et al.. (2010). Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology. 28(15_suppl). 5505–5505. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Virag Dandekar Breakdown of academic impact, for papers by J. Cheng Breakdown of academic impact, for papers by O. Nascimben Breakdown of academic impact, for papers by Jst Sham Breakdown of academic impact, for papers by A. Price Breakdown of academic impact, for papers by Cyril Abdeddaim Breakdown of academic impact, for papers by Yasmine Baca Breakdown of academic impact, for papers by A. Biete Breakdown of academic impact, for papers by Hammouda Boussen Breakdown of academic impact, for papers by Samuel Marcrom
Rankless by CCL
2026